US EditionProstate cancer screening could prevent 1,500 deaths a year
The study followed 162,236 men over 23 years, showing a 13% reduction in prostate cancer deaths but highlighting ongoing concerns about overdiagnosis and excess cases.
- Long-Term follow-up of the European Randomized Study of Screening for Prostate Cancer showed prostate cancer mortality was 13% lower in the PSA screening group versus the control group after median follow-up 23 years.
- With 162,236 men enrolled, the trial began in 1993 in the Netherlands and Belgium, with median age 60 years and eligibility for men ages 50 to 74.
- Most centers used a PSA cutoff 3.0 ng/mL, with men in the screening group averaging two screenings; 83% underwent at least one, 28% had positive results, and biopsy compliance was 89%.
- Despite improved ratios, the number needed to invite fell from 628 to 456, and the excess incidence decreased to 27 extra cases per 1,000 men, with harms like overdiagnosis remaining a concern.
- Andrew Vickers, PhD wrote `there can be little doubt that PSA screening reduces prostate cancer mortality` but noted diagnostic and treatment evolution means the effect estimate reflects an outdated approach.
7 Articles
7 Articles
Evening Standard
Study shows prostate cancer screening can ‘reduce deaths’ as UK scheme assessed
Experts called for a ‘targeted’ screening approach to prevent overdiagnosis.
MedPage Today
Anti-Aging, Acupuncture and Health NewsPSA Screening Reduces Prostate Cancer Deaths, Long-Term Data Show
(MedPage Today) -- A sustained reduction in deaths from prostate cancer was observed with prostate-specific antigen (PSA) testing in long-term follow-up results from the European Randomized Study of Screening for Prostate Cancer. After a median...
expert reaction to 23 year follow up data from The European Randomized Study of Screening for Prostate Cancer
A study and related editorial published in the New England Journal of Medicine looks at follow up data from the European Study of Prostate Cancer Screening. Dr Matthew Hobbs, Director of Research at Prostate Cancer UK, said: “The ERSPC trial was one of the largest prostate cancer screening studies ever conducted, and 23 years on it is still providing valuable insights. “As researchers have continued to track men from the trial, the overall ba…
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
